Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Gross Margin (2023 - 2025)

Krystal Biotech's Gross Margin history spans 3 years, with the latest figure at 93.84% for Q4 2025.

  • For Q4 2025, Gross Margin fell 72.0% year-over-year to 93.84%; the TTM value through Dec 2025 reached 94.08%, up 98.0%, while the annual FY2025 figure was 94.08%, 98.0% up from the prior year.
  • Gross Margin for Q4 2025 was 93.84% at Krystal Biotech, down from 95.64% in the prior quarter.
  • Across five years, Gross Margin topped out at 97.39% in Q3 2023 and bottomed at 91.45% in Q2 2024.
  • The 3-year median for Gross Margin is 94.07% (2025), against an average of 93.96%.
  • The largest annual shift saw Gross Margin plummeted -537bps in 2024 before it soared 361bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 93.19% in 2023, then increased by 1bps to 94.57% in 2024, then fell by -1bps to 93.84% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Gross Margin are 93.84% (Q4 2025), 95.64% (Q3 2025), and 92.54% (Q2 2025).